Increasing evidence for the safety and efficacy of alcohol septal ablation during medium- and long-term follow-up

Clinical Research in Cardiology

Volumn 96, Issue 12, 2007, Pages 851-855

  Pauschinger, Matthias ^a   Keren, Andre ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Alcohol septal ablation; Hypertrophic cardiomyopathy; TASH PTSMA

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; ALCOHOL SEPTUM ABLATION; CASE REPORT; CATHETER ABLATION; CONTROLLED STUDY; DEFIBRILLATOR; EDITORIAL; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART LEFT VENTRICLE WALL; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MUSCLE RESECTION; PACEMAKER; TREATMENT OUTCOME;

CARDIOMYOPATHY, HYPERTROPHIC; ETHANOL; FOLLOW-UP STUDIES; HEART SEPTUM; HUMANS; SOLVENTS; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 36448933772     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0580-2     Document Type: Editorial

References (40)

1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93:841-842
2. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785-789
3. Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308-1320
4. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114:2232-2239
5. Nishimura Ra, Holmes DR Jr (2004) Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med 350:1320-1327
6. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295- 303
7. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P (2005) The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 45(7):1076-1080
8. Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, Thaman R, Mogensen J, McKenna WJ (2006) Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 27(16):1933-1941
9. Robbins RC, Stinson EB (1996) Longterm results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 111(3):586-594
10. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA (2005) Longterm effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46:470-476
11. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, Siu S, Ralph-Edwards A, Rakowski H (2005) Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 111(16):2033-2041
12. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED (2003) Task force on clinical expert consensus documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. College of Cardiology/ European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42(9):1687-1713
13. Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346(8969):211-214
14. Kuhn H, Gietzen F, Leuner CH, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new catheter-based concept of treatment. Eur Heart J 18:846-851
15. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-months follow-up in 25 patients. J Am Coll Cardiol 31:252-258
16. Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98:2415-2421
17. Gietzen FH, Leuner J, Raute-Kreinsen U, Dellmann AM, Hegselmann J, Strunk-Mueller C, Kuhn HJ (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J 20:1342-1354
18. Kuhn H, Gietzen FH, Leuner C, Schafers M, Schober O, Strunk-Muller C, Obergassel L, Freick M, Gockel B, Lieder F, Raute-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(Suppl 4)4:41-54
19. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidt HK, Gleichmann U, Horstkotte D (2004) Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 5(5):347-355
20. Kuhn H, Seggewiss H, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L (2004) Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry. Z Kardiol 93(1):23-31
21. Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boekstegers P, Neuhaus L, Seipel L, Horstkotte D (2005) Catheter- based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society. Z Kardiol 94(8):516-523
22. Alam M, Dokainish H, Lakkis N (2006) Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. A systematic review of published studies. J Interv Cardiol 19:319-327
23. Knight CJ (2006) Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Heart 92:1339-1344
24. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Müller C, Kuhn H (2004) Transoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit and short term results in elderly patients. Heart 90:638-644
25. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD (2001) Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy. J Am Coll Cardiol 38(7):1994-2000
26. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38: 1701-1706
27. Ralph-Edwards A, Woo A, McCrindle BW, Shapero JL, Schwartz L, Rakowski H, Wigle ED, Williams WG (2005) Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 129:351-358
28. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, Sachdev B, Thaman R, McKenna WJ (2002) Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. Eur Heart J 23:1617-1624
29. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, Nishimura RA (2004) The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 44:2044-2053
30. Haldman AW, Wu KC, Abraham TP, Cameron DE (2007) Myectomy or alcohol septal ablation. J Am Coll Cardiol 49:358-360
31. Lawrenz T, Obergassel L, Lieder F, Leuner C, Strunk-Mueller C, Meyer Zu Vilsendorf D, Beer G, Kuhn H (2005) Tanscoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 28:295-300
32. Boltwood CM Jr, Chien W, Ports T (2004) Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med 351:1914-1915
33. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients. Predictors of hemodynamic and clinical response. Clin Res Cardiol 96:863-872
34. Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L (2007) Longterm follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 96:855-862
35. Chang SM, Lakkis NM, Franklin J, Spencer WH 3rd, Nagueh SF (2004) Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 109:824-827
36. Yoerger DY, Picard MH, Palacios IF, Vlahakes GJ, Lowry PA, Fifer MA (2006) Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 97:1511-1514
37. Keren A, Poteckin M, Mazouz B, Medina A, Banai S, Chenzbraun A, Khoury Z, Levin G (2007) Late inhospital pressure gradient measurements improve prediction of longterm outcome of alcohol septal ablation in hypertrophic cardiomyopathy. IMAJ 9:239-242
38. Schultz-Menger J, Strohm O, Waigand J, Uhlich F, Dietz R, Friedrich MG (2000) The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. Circulation 101:1764-1766
39. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ (2007) Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hyoertrophic obstructive cardiomyopathy. J Am Coll Cardiol 49:350-357
40. Keren A, Syrris P, McKenna WJ (2008) Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med (in press)